ArticleFrontiers in endocrinology2025
Comparison of incidence trends of early-onset and late-onset type 2 diabetes in the Asia-Pacific region, 1990-2021: a join point regression analysis based on the global burden of disease study 2021.
Article in Frontiers in endocrinology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed.
- Analysis and prediction of the trends in diabetes mellitus mortality in Chinese residents from 2008 to 2021.Archives of public health = Archives belges de sante publique · 2026Article
- Association of continuous glucose monitoring metrics with early diabetic kidney disease in early-onset type 2 diabetes.Frontiers in endocrinology · 2026Article
- Review
- Interaction of triglyceride glucose index and weight-adjusted waist circumference index in the risk of diabetes: from a national cohort study.BMC endocrine disorders · 2025Article
- Interaction and overall effects of underweight, low muscle mass, malnutrition, and inflammation on early-onset mild cognitive impairment in type 2 diabetes.Frontiers in aging neuroscience · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: This study evaluated the incidence trends of early-onset (diagnosed at ages 15-39) and late-onset (diagnosed at age 40 and above) type 2 diabetes mellitus (T2DM) in the Asia-Pacific region, including the World Health Organization (WHO) South-East Asia Region (SEARO) and Western Pacific Region (WPRO), and assessed the impact of the COVID-19 pandemic. Methods: Using data from the Global Burden of Diseases Study (GBD) 2021, we analyzed trends in age-standardized incidence rate (ASIR) using Join point regression to determine annual percentage change (APC). To assess the pandemic's impact, we calculated excess incidence for 2020 and 2021 by subtracting predicted ASIR from observed ASIR. Results: In recent years, particularly during the COVID-19 pandemic, the ASIR for early-onset T2DM in the Asia-Pacific region accelerated significantly. SEARO's APC rose from 2.24% between 2011-2019 to 5.45% between 2019-2021. Similarly, WPRO's APC increased from 1.71% between 1999-2017 to 5.01% between 2017-2021. In 2021, the ASIR for early-onset T2DM was 269.6 per 100,000 in WPRO and 248.4 per 100,000 in SEARO. Conversely, late-onset T2DM ASIR growth in SEARO slowed after 2017 (APC 1.92% for 2005-2017 Conclusions: This study reveals a significant recent increase in early-onset T2DM incidence in the Asia-Pacific region, highlighting the need for targeted public health interventions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.